Pharmacological aspects of experimental headache models in relation to acute antimigraine therapy

被引:96
作者
De Vries, P
Villalón, CM
Saxena, PR
机构
[1] Erasmus Univ, Med Ctr Rotterdam EMCR, Dept Pharmacol, Dutch Migraine Res Grp, NL-3000 DR Rotterdam, Netherlands
[2] Erasmus Univ, Med Ctr, Cardiovasc Res Inst COEUR, NL-3000 DR Rotterdam, Netherlands
[3] CINVESTAV, IPN, Dept Farmacol & Toxicol, Secc Terapeut Expt, Mexico City 14000, DF, Mexico
关键词
5-hydroxytryptamine; 5-HT receptor; migraine; migraine model; serotonin; sumatriptan; triptan;
D O I
10.1016/S0014-2999(99)00197-1
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The last decade has witnessed a tremendous progress in the acute therapy of migraine, with sumatriptan, belonging to a new class of drugs, now known as 5-HT(1B/1D/1F) receptor agonists, leading the way. The undoubted success of sumatriptan stimulated the development of new triptans as well as other suitable pharmacological tools and experimental models to probe into complex migraine mechanisms. In this review, we discuss the main experimental models for migraine, against the background of the disease pathophysiology and 5-HT receptors considered most important for migraine therapy. We believe that the use of these migraine models will provide even better treatment for migraine patients in the next millennium. (C) 1999 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:61 / 74
页数:14
相关论文
共 142 条
  • [11] BRANCHEK TA, 1995, EXPT HEADACHE MODELS, P123
  • [12] Role of endothelin in mediating neurogenic plasma extravasation in rat dura mater
    Brandli, P
    Loffler, BM
    Breu, V
    Osterwalder, R
    Maire, JP
    Clozel, M
    [J]. PAIN, 1996, 64 (02) : 315 - 322
  • [13] AUTORADIOGRAPHIC CHARACTERIZATION AND LOCALIZATION OF 5-HT(1D) COMPARED TO 5-HT(1B) BINDING-SITES IN RAT-BRAIN
    BRUINVELS, AT
    PALACIOS, JM
    HOYER, D
    [J]. NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 1993, 347 (06) : 569 - 582
  • [14] ANTIMIGRAINE DRUG SUMATRIPTAN INCREASES BLOOD-FLOW VELOCITY IN LARGE CEREBRAL-ARTERIES DURING MIGRAINE ATTACKS
    CAEKEBEKE, JFV
    FERRARI, MD
    ZWETSLOOT, CP
    JANSEN, J
    SAXENA, PR
    [J]. NEUROLOGY, 1992, 42 (08) : 1522 - 1526
  • [15] Castro E, 1997, J NEUROCHEM, V69, P2123
  • [16] Identification of (-)-cis-6-acetyl-4S-(3-chloro-4-fluoro-benzoylamino)-3,4-dihydro-2,2-dimethyl-2H-benzo[b]pyran-3S-ol as a potential antimigraine agent
    Chan, WN
    Evans, JM
    Hadley, MS
    Herdon, HJ
    Jerman, JC
    Parsons, AA
    Read, SJ
    Stean, TO
    Thompson, M
    Upton, N
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1999, 9 (02) : 285 - 290
  • [17] EVOLUTION OF A NOVEL SERIES OF [(N,N-DIMETHYLAMINO)PROPYL]ANILIDE AND PIPERAZINYLBENZANILIDES AS THE FIRST SELECTIVE 5-HT1D ANTAGONISTS
    CLITHEROW, JW
    SCOPES, DIC
    SKINGLE, M
    JORDAN, CC
    FENIUK, W
    CAMPBELL, IB
    CARTER, MC
    COLLINGTON, EW
    CONNOR, HE
    HIGGINS, GA
    BEATTIE, D
    KELLY, HA
    MITCHELL, WL
    OXFORD, AW
    WADSWORTH, AH
    TYERS, MB
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 1994, 37 (15) : 2253 - 2257
  • [18] COHEN ML, 1998, 4 IUPHAR SAT M SER R
  • [19] Naratriptan: Biological profile in animal models relevant to migraine
    Connor, HE
    Feniuk, W
    Beattie, DT
    North, PC
    Oxford, AW
    Saynor, DA
    Humphrey, PPA
    [J]. CEPHALALGIA, 1997, 17 (03) : 145 - 152
  • [20] 5-HYDROXYTRYPTAMINE CONTRACTS HUMAN CORONARY-ARTERIES PREDOMINANTLY VIA 5-HT2 RECEPTOR ACTIVATION
    CONNOR, HE
    FENIUK, W
    HUMPHREY, PPA
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 1989, 161 (01) : 91 - 94